NanoViricides engages Aagami to seek licensing, partnering opportunities

NanoViricides has engaged Aagami, Inc. for business development, specifically to seek licensing and partnering opportunities for our assets and platform technology. The Company is currently seeking licensing and partnering opportunities for its key asset, NV-387, and its key nanoviricides platform technology. The Company has engaged Aagami, a small boutique firm, to help with these efforts for the regions of India and Japan, noting the firm’s strength and specialty in these regions for licensing and partnering endeavors. NV-387 has successfully completed a Phase I human clinical trial in healthy subjects in India. No adverse events were reported even at the highest dose levels tested in the single-ascending dose or the multiple-ascending dose cohorts in the clinical trial. Two oral formulations of NV-387, Oral Syrup, and Oral Gummies were tested in this clinical trial/ NV-387 is now ready for Phase II clinical trials in any of its multiple indications.